OncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX) in a research note released on Saturday. The firm issued a sell rating on the stock.

Separately, Needham & Company LLC reissued a buy rating and issued a $4.25 target price on shares of OncoCyte in a research note on Friday, August 9th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of Hold and a consensus price target of $4.06.

OncoCyte Trading Up 11.3 %

Shares of OCX stock opened at $3.34 on Friday. OncoCyte has a fifty-two week low of $2.08 and a fifty-two week high of $4.34. The stock has a 50 day moving average price of $3.13 and a two-hundred day moving average price of $2.93.

OncoCyte (NASDAQ:OCX) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.36) EPS for the quarter. The firm had revenue of $0.10 million for the quarter. OncoCyte had a negative net margin of 3,558.46% and a negative return on equity of 149.88%.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.